Get the Stockscreener App
4.88
55.41%
1.74
After Hours:
4.48
-0.40
-8.20%
Eyenovia Inc stock is traded at $4.88, with a volume of 33.11M.
It is up +55.41% in the last 24 hours and up +373.79% over the past month.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
See More
Previous Close:
$3.14
Open:
$4.29
24h Volume:
33.11M
Relative Volume:
16.13
Market Cap:
$4.81M
Revenue:
$31,800
Net Income/Loss:
$-37.83M
P/E Ratio:
-6.8732
EPS:
-0.71
Net Cash Flow:
$-30.64M
1W Performance:
+192.22%
1M Performance:
+373.79%
6M Performance:
-30.44%
1Y Performance:
-92.18%
1-Day Range:
$3.53
$5.88
1-Week Range:
$1.62
$5.88
52-Week Range:
$0.85
$124.80
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Compare EYEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
4.88 | 4.81M | 31,800 | -37.83M | -30.64M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia (EYEN) Stock Skyrockets Over 23% on Nasdaq, Showing Explosive Short-Term Rally - Daily Chhattisgarh News
Eyenovia (EYEN) Stock Explodes Following Amended Loan Agreement Terms: What's Going On? - Benzinga
Eyenovia On May 30, Enters Third Amendment To Loan And Security AgreementSEC Filing - marketscreener.com
eyenovia amends loan agreement, limits stock conversion option - Investing.com
Eyenovia Amends Loan Agreement with Avenue Capital - TipRanks
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.
Eyenovia provides update on potential merger and Optejet development - MSN
Eyenovia Provides Updates on Potential Merger with Betaliq and D - GuruFocus
Eyenovia Advances Merger Talks With Betaliq And Targets FDA Filing For Optejet Device - Nasdaq
Eyenovia (EYEN) Shares Explode On Betaliq Merger Progress, Strong Q1 Financials - Benzinga
Eyenovia Reports Q1 2025 Progress and Financials - TipRanks
Eyenovia advances on merger talks, cuts cash burn, eyes September FDA filing By Investing.com - Investing.com South Africa
Eyenovia advances on merger talks, cuts cash burn, eyes September FDA filing - Investing.com Australia
Eyenovia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Eyenovia (EYEN) Pursues Merger with Betaliq and Advances Optejet Device | EYEN Stock News - GuruFocus
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results | EYEN Stock News - GuruFocus
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results - The Manila Times
Eyenovia, Inc. Provides Merger Update with Betaliq and Financial Results for Q1 2025 - Nasdaq
Eyenovia Provides Updates On Potential Merger With Betaliq And Development Of The Optejet User Filled Device (Ufd), And Reports First Quarter 2025 Financial Results - marketscreener.com
Eyenovia Provides Updates on Potential Merger with Betaliq - GlobeNewswire
Eyenovia Slashes Cash Burn 70% While Racing Toward Major FDA Filing and Merger Deal - Stock Titan
Public market insider buying at TC Energy (TRP) - The Globe and Mail
Eyenovia Delays Q1 2025 10-Q Filing - TipRanks
3 Monster Stocks in the Making - The Globe and Mail
‘Buy MSFT, AMZN, GOOGL, and PLTR Stocks,’ Says Wedbush - The Globe and Mail
My 3 Favorite Stocks to Buy Right Now - The Globe and Mail
Eyenovia Faces Nasdaq Delisting Over Equity Shortfall By Investing.com - Investing.com India
Eyenovia Faces Nasdaq Delisting Over Equity Shortfall - Investing.com
EYENEyenovia Inc Latest Stock News & Market Updates - Stock Titan
Where Will Walmart Stock Be in 1 Year? - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Eyenovia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EYENOVIA, INC. SEC 10-K Report - TradingView
Eyenovia Inc expected to post a loss of $7.20 a shareEarnings Preview - TradingView
Eyenovia (EYEN) Advances with Optejet User Filled Device Development | EYEN Stock News - GuruFocus
Eyenovia Provides Development Update on Optejet User Filled Devi - GuruFocus
Eyenovia nears regulatory submission for Optejet UFD device By Investing.com - Investing.com South Africa
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) - The Manila Times
Eyenovia nears regulatory submission for Optejet UFD device - Investing.com
Eyenovia provides development update on Optejet UFD - TipRanks
Revolutionary Eye Drug Device Passes Critical Tests: Eyenovia's Game-Changing Innovation - Stock Titan
Mydriasis Market Predicted to See Upsurge Through 2034, - openPR.com
Mydriasis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharma - Barchart.com
Eyenovia Delays Yearly Report Filing - TipRanks
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Eyenovia’s Strategic Position and Uncertain Prospects: Hold Rating Amid Merger and Growth Challenges - TipRanks
Eyenovia falls on plans to seek reverse merger - MSN
Eyenovia Enters Into Non-Binding Letter of Intent to Effect Reverse Merger With Betaliq - VisionMonday.com
Eyenovia And Betaliq Announce Potential Reverse Merger - Nasdaq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks - Yahoo
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):